For citations:
Stukan AI, Goryainova AY, Lymar EV, Sharov SV, Antipova VV. Molecular features evaluation of metastatic foci as the basis for metastatic breast cancer treatment personalization. Is there a place of CDK4/6-inhibitors in late-line therapy after chemotherapeutic regimens? Meditsinskiy sovet = Medical Council. 2021;(20):54-61. (In Russ.) https://doi.org/10.21518/2079-701X-2021-20-54-61